pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Opdivo · news · pharmadog
← back to Opdivo
News mentioning Opdivo
54
stories
6d
J&J’s disappointing Q3, RevMed’s subgroup data, BMS’ ‘mixed’ results, Caribou’s cutback
biospace
7d
BMS’ Phase 3 win for lung drug clouded by high-dose miss
biospace
8d
BMS doubles up with pivotal wins in lung disease, solid tumor that offer hope for post-patent cliff growth
fiercebiotech
12d
Ono pays $80M for regional rights to trio of Biohaven IgG degraders, including phase 3 Grave’s asset
fiercebiotech
12d
Q3 layoffs down YOY, with 90% fewer biopharma employees affected
biospace
12d
Halozyme prevails in patent fight with Merck; Enliven readies anticipated leukemia trial
biopharma dive
14d
Significant stock movers of September: Viking soars, Longeveron slides
biospace
17d
BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffs
biospace
Sep 14, 26
Unlocking cell surface protein research with site-specific labeling
biospace
Sep 14, 26
5 drugmakers chasing Merck and Moderna in the cancer vaccine race
biospace
Sep 9, 26
A new immuno-oncology play raises $225M for a next-generation drug
biopharma dive
Sep 3, 26
Akeso, Summit cancer drug confirms lung cancer survival benefit
biopharma dive
Sep 3, 26
Replimune’s melanoma drug would have been rejected again if not for senior CBER official
biospace
Sep 2, 26
Stripped of AstraZeneca safety net, BMS could face ‘carnage’ if high-risk clinical trial fails
biospace
Aug 24, 26
Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone
biospace
Aug 17, 26
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
biopharma dive
Aug 10, 26
BMS picks Texas for new $2.3B manufacturing campus
biospace
Aug 6, 26
Replimune rebounds to win FDA approval of melanoma drug
biopharma dive
Aug 6, 26
Third time’s the charm for Replimune as melanoma drug earns FDA greenlight
biospace
Aug 6, 26
FDA Approves New Engineered Viral Immunotherapy for Patients with Treatment-Resistant Advanced Melanoma
fda press
Aug 5, 26
No deal between AstraZeneca and BMS, senior source insists: Reuters
biospace
Aug 5, 26
Chaotic adcomms threaten to derail FDA’s bid to renew trust after Makary, Prasad
biospace
Aug 5, 26
Rumors of biggest pharma merger ever drop amid Q2 earnings, contentious FDA adcomms
biospace
Aug 4, 26
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
biospace
Aug 3, 26
An AstraZeneca-Bristol Myers megamerger? Wall Street isn’t thrilled.
biopharma dive
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Aug 3, 26
Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
fiercebiotech
Jul 30, 26
Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy
biospace
Jul 30, 26
Replimune melanoma drug wins support of FDA panel
biopharma dive
Jul 30, 26
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
← prev
page 1 of 2
next →
